BACKGROUND AND OBJECTIVES: Connexin43 (cx43), a gap junction protein, is implicated in the suppression of tumor cell growth. Numerous cancer cells show a reduction or loss of cx43 expression compared to their normal counterparts. Our previous studies suggest that cx43 expression is decreased in a variety of human brain tumor cell lines. To further investigate the role of cx43 in the development of human gliomas, we performed the present study on human glioma grades I-IV. METHODS: Immunohistochemistry was performed on paraffin-embedded tissue sections of 18 human gliomas to analyze the expression levels of cx43 in different stages of human gliomas. RESULTS: High levels of cx43 were observed in all normal brain tissue and in glioma grades I and II. In contrast, the expression of cx43 was very weak in grade III gliomas and almost undetectable in grade IV gliomas. CONCLUSIONS: Our data support the hypothesis that reduction of cx43 is involved in the progression of human gliomas.
BACKGROUND AND OBJECTIVES:Connexin43 (cx43), a gap junction protein, is implicated in the suppression of tumor cell growth. Numerous cancer cells show a reduction or loss of cx43 expression compared to their normal counterparts. Our previous studies suggest that cx43 expression is decreased in a variety of humanbrain tumor cell lines. To further investigate the role of cx43 in the development of humangliomas, we performed the present study on humanglioma grades I-IV. METHODS: Immunohistochemistry was performed on paraffin-embedded tissue sections of 18 humangliomas to analyze the expression levels of cx43 in different stages of humangliomas. RESULTS: High levels of cx43 were observed in all normal brain tissue and in glioma grades I and II. In contrast, the expression of cx43 was very weak in grade III gliomas and almost undetectable in grade IV gliomas. CONCLUSIONS: Our data support the hypothesis that reduction of cx43 is involved in the progression of humangliomas.
Authors: Eliseo A Eugenin; Daniel Basilio; Juan C Sáez; Juan A Orellana; Cedric S Raine; Feliksas Bukauskas; Michael V L Bennett; Joan W Berman Journal: J Neuroimmune Pharmacol Date: 2012-03-23 Impact factor: 4.147
Authors: Christina L Grek; Zhi Sheng; Christian C Naus; Wun Chey Sin; Robert G Gourdie; Gautam G Ghatnekar Journal: Curr Opin Pharmacol Date: 2018-05-24 Impact factor: 5.547